Thank you for your interest in the Cell Based Assays & Bioanalytical Method Development conference! The 2011 conference was our best yet, featuring:
- Detailed domestic and international regulatory updates
- In-depth examinations of proper statistical analysis methods for cutpoint and outlier determination
- Case studies of breakthroughs in cell engineering, virology assays, biomarker assays, LC-MS protein analysis, cell-based assays for NAbs and much more!
We are hard at work on next year's event, so watch this space for updates throughout the year. I also invite you to subscribe to the Future of BioPharma Blog for the latest industry news and event information. We hope to see you in the Bay Area in fall 2012!
If you are interested in speaking opportunities, please contact Matt Greenbaum, Conference Producer
To discuss sponsorship and exhibition options, please contact Adam Lennon, Sales Manager
 |
 |
 |
Featured Speakers
 |
KEYNOTE: Jack Ragheb FDA |
 |
KEYNOTE: Michael Tovey NATIONAL CENTER FOR SCIENTIFIC RESEARCH, FRANCE |
 |
KEYNOTE: Shan Chung GENENTECH |
 |
Shan Wang STANFORD UNIVERSITY |
 |
Lindsay King PFIZER |
 |
Hans Ulrichts ABLYNX |
 |
Xiao-Yan Cai MERCK RESEARCH LABORATORIES |
 |
Thomas Baer STANFORD PHOTONICS RESEARCH CENTER |
State-of-the-Art Updates
- Forecasting and adapting to regulatory guidelines
from U.S. and European authorities - Technical review and implementation of the latest whitepapers concerning effector function and free vs total PK immunoassays
In-Depth Workshops
- Method Development for Liquid Chromatrography
– Mass Spectrometry Applications in the Clinical Laboratory Setting - Fundamentals of Cell Based Assays: Tactics and Troubleshooting
- Establishing Acceptance Criteria, Cutpoints, and Outliers
Conference concludes with a special in-depth joint session analyzing the most specialized assays with unusual needs including:
- Bioanalytical tests for comparison studies in the development of biosimilars
- Justification of Nanobody batch-release potency assays
- Novel cell based assays using reporter genes to track
antiviral neutralization - MOA-reflective bioassays for bi-specific antibodies
—Scientist, PEREGRINE PHARMACEUTICALS